{"drugs":["Varicella Zoster Immune Globulin","Varicella-Zoster Immune Globulin","Varizig"],"mono":{"0":{"id":"923340-s-0","title":"Generic Names","mono":"Varicella-Zoster Immune Globulin"},"1":{"id":"923340-s-1","title":"Dosing and Indications","sub":[{"id":"923340-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Post-exposure prophylaxis - Varicella:<\/b> administer as soon as possible following exposure (ideally within 96 hours), but within 10 days after exposure<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 40.1 kg or greater) 625 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 30.1 to 40 kg) 500 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> consider a second dose for patients who have additional exposure more than 3 weeks after initial administration<\/li><\/ul>"},{"id":"923340-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Post-exposure prophylaxis - Varicella:<\/b> administer as soon as possible following exposure (ideally within 96 hours), but within 10 days after exposure<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 2 kg or less) 62.5 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 2.1 to 10 kg); 125 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 10.1 to 20 kg); 250 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 20.1 to 30 kg); 375 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 30.1 to 40 kg) 500 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> (body weight, 40.1 kg or greater) 625 international units IM<\/li><li><b>Post-exposure prophylaxis - Varicella:<\/b> consider a second dose for patients who have additional exposure more than 3 weeks after initial administration<\/li><\/ul>"},{"id":"923340-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric patients:<\/b> use caution "},{"id":"923340-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Post-exposure prophylaxis - Varicella<br\/>"}]},"3":{"id":"923340-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923340-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic or other severe systemic reaction to immune globulins, history of; use not recommended<\/li><li>IgA deficiency, with IgA antibodies and a history of hypersensitivity; anaphylactoid reaction may occur<\/li><\/ul>"},{"id":"923340-s-3-10","title":"Precautions","mono":"<ul><li>coagulation disorder, any; administer IM formulation only if benefit outweighs the risk<\/li><li>concomitant use of live vaccines; defer vaccination for 3 months after varicella zoster immune globulin<\/li><li>geriatric patients with increased risk of thrombotic events<\/li><li>human plasma derivative product; infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>hypersensitivity reactions may occur; discontinue immediately and institute appropriate treatment<\/li><li>hyperviscosity, known or suspected (including cryoglobulins, fasting chylomicronemia\/markedly high triglycerides, or monoclonal gammopathies); increased risk of thrombotic events; monitoring recommended<\/li><li>IgA-containing product (less than 40 mcg\/mL); patients with antibodies to IgA have increased risk of severe hypersensitivity reactions and anaphylaxis<\/li><li>thrombocytopenia, severe; administer IM formulation only if benefit outweighs the risk<\/li><li>thrombotic events may occur; increased risk with history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and known or suspected hyperviscosity; monitoring recommended<\/li><li>report suspected adverse events or infections to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923340-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"923340-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"923340-s-4","title":"Drug Interactions","sub":{"2":{"id":"923340-s-4-15","title":"Moderate","mono":"<ul><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"923340-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (overall, 2%; pregnant women, 9%)<\/li><li><b>Neurologic:<\/b>Headache (overall, 2%; pregnant women, 4%)<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Blood coagulation disorder, Deep venous thrombosis, Thrombosis<br\/>"},"6":{"id":"923340-s-6","title":"Drug Name Info","sub":{"0":{"id":"923340-s-6-17","title":"US Trade Names","mono":"<ul><li>Varicella Zoster Immune Globulin<\/li><li>Varizig<\/li><\/ul>"},"2":{"id":"923340-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"923340-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923340-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923340-s-7","title":"Mechanism Of Action","mono":"Varicella zoster immune globulin (human) is a derivative of human plasma that confers passive immunity against the varicella zoster virus. It primarily contains the immunoglobulin G (IgG) class of varicella zoster antibodies.<br\/>"},"8":{"id":"923340-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"923340-s-8-23","title":"Absorption","mono":"Tmax, IM: 4.5 days <br\/>"},"3":{"id":"923340-s-8-26","title":"Excretion","mono":"Total body: 0.204 mL\/day <br\/>"},"4":{"id":"923340-s-8-27","title":"Elimination Half Life","mono":"26.2 days (variable from person to person) <br\/>"}}},"9":{"id":"923340-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IM use only<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute with 1.25 mL of provided sterile diluent only; inject slowly into vial at an angle<\/li><li>gently tilt and invert vial to wet pellet; swirl to dissolve (less than 10 minutes); avoid frothing and do NOT shake vial<\/li><li>administer within 12 hours of reconstitution, if refrigerated; discard any unused portion<\/li><li>divide IM dose in 2 or more injection sites depending on patient size; do NOT exceed 3 mL per site<\/li><li>inject into deltoid muscle or anterolateral aspects of upper thigh; avoid IM injection into the gluteal region due to risk of injury to sciatic nerve; if gluteal region must be used, inject only in the upper, outer quadrant<\/li><\/ul><\/li><\/ul>"},"10":{"id":"923340-s-10","title":"Monitoring","mono":"<ul><li>reduction in severity of clinical signs and symptoms of varicella zoster infection may indicate efficacy<\/li><li>blood viscosity assessment; consider at baseline in patients at risk for hyperviscosity (eg, patients with cryoglobulins, fasting chylomicronemia, severe hypertriglyceridemia, or monoclonal gammopathies)<\/li><\/ul>"},"11":{"id":"923340-s-11","title":"How Supplied","mono":"<b>Varizig<\/b><br\/><ul><li>Intramuscular Powder for Solution: 125 U<\/li><li>Intramuscular Solution: 125 IU\/1.2 ML<\/li><\/ul>"},"13":{"id":"923340-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug will not prevent infection by varicella-zoster virus if patient has already been infected, but it may modify severity of the illness.<\/li><li>Despite screening and testing, human plasma products carry a low risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare provider.<\/li><li>This drug may cause headache or pain at the injection site.<\/li><li>Instruct patient to immediately report signs or symptoms of allergic or anaphylactic reactions.<\/li><li>Advise patient to avoid live virus vaccines for about 3 months after receiving varicella-zoster immune globulin.<\/li><\/ul>"}}}